Further Evidence for the Role of Probiotics in Depression Recent scientific research has been uncovering the intestinal microbiome's impact on the nervous system's development and functioning. The gut microbiome and specific neurobiological pathways are known as the "microbiome-gut-brain axis.” There are two main paths through which information can flow [...]
A promising new therapeutic approach for major depressive disorder targets the microbiota-gut-brain axis: novel evidence Major depressive disorder is one of the most common mental disorders and in some individuals it can result in severe impairments that interfere with or limit the ability to carry out major life activities. The concept [...]
The potential contribution of the gut-muscle axis to the pathophysiology of sarcopenia and reduced physical capacity in COPD patients Chronic obstructive pulmonary disease (COPD) is an inflammatory condition of the respiratory system which can also affect multiple organs. Most patients with COPD develop muscle weakness and atrophy, which contribute to functional [...]
Autism spectrum disorders have an increasing prevalence characterized by enormous individual, family and social costs. There are growing interest and more resources addressed to researching the causes of this disease, which are still far from being fully and exhaustively defined. However, an interaction between genetic and environmental factors is implicated, converging [...]
Reduction in seizures following add-on probiotic therapy in patients with drug-resistant epilepsy. Drug-resistant epilepsy (DRE) occurs in 25-30 per cent of patients with epilepsy (1), and current alternative therapies have shown limited effectiveness. The gut microbiota is known to regulate immunity and inflammation, metabolism, and neuronal signaling pathways (2), and alterations [...]
De Simone Formulation combined with rifaximin positively affect the neurometabolic profile in a rat model of type C hepatic encephalopathy. Type C hepatic encephalopathy (HE) is a neuropsychiatric disease caused by hepatic dysfunction secondary to chronic liver disease. Management of type C HE remains an important challenge because treatment options are [...]
A federal jury in the United States District Court for the District of Maryland unanimously ruled on Nov. 18 in favor of myself and ExeGi Pharma, which distributes my Formulation in the US, against VSL Inc, Leadiant and Alfasigma, for False Advertising, Unjust Enrichment and Unpaid Royalties. The jury unanimously found [...]
Infographic: May 2017 The probiotic formulation of Pr. De Simone has been tested in over 5000 patients of all ages: 33 330 adult participants 1 682 children in pediatric studies 295 participants in geriatric studies The numerous studies and the large panel of participants have demonstrated the safe use [...]
Infographic: May 2017 The Simone Formulation has been tested worldwide Among the probiotics being studied, many are tested at a national level and in a confidential manner. The Simone Formulation is the subject of worldwide studies and international publications: 35 studies in Europe 11 studies in India 9 studies in [...]